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ABSTRACT 
Indinavir plasma levels are associated with antiretroviral efficacy however few data is 
available regarding toxicity. We assessed the relationship between indinavir 
pharmacokinetic (PK) characteristics and severe nephrolithiasis as well as other severe or 
serious adverse reactions (SAR). Patients included in the ANRS CO8 APROCO-
COPILOTE cohort and receiving indinavir 800 mg thrice daily as first line protease 
inhibitor, were eligible for this study. To be included in the analysis, their plasma sample at 
month 1 (M1) had to be available (n=282) to estimate, using population PK modelling, 
indinavir PK characteristics, i.e. maximum (Cmax) and trough plasma (Cres) concentrations, 
area under the curve (AUC) and observed/predicted concentrations ratio (CR). A Cox 
model was used to estimate the independent effect of Cmax, Cres, AUC and CR on the hazard 
of severe nephrolithiasis and SAR. At M1, median Cmax was 6 205 ng/mL, Cres: 631 ng/mL, 
AUC: 24 242 ng.h/mL and CR: 0.6. After a median follow-up of 12 months, 11% of 
patients (30/282) had experienced at least one SAR among which 12 were nephrolithiasis. 
In the multivariate analyses, early high indinavir Cres (i.e. ≥ 1000 ng/mL at M1) was 
associated with a higher rate of severe nephrolithiasis (HR=6.7; 95% confidence 
interval=1.8-25.2; p<0.01) and was also associated with a higher rate of all SAR but only 
when nephrolithiasis were included among those cases. Prospective and early indinavir Cres 
determination should be recommended in the patient’s care management and dosage 
adjustments. 
 
Keywords: Indinavir, plasma levels, nephrolithiasis, toxicity, pharmacokinetic. 
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INTRODUCTION 
One of the main drawbacks of Highly Active Antiretroviral Therapy (HAART) is 
toxicity, leading to treatment discontinuations and limitation of treatment options. Among 
baseline characteristics, high plasma HIV RNA, elevated aspartate animotransferase (AST), 
reduced creatinine clearance, positive hepatitis C-virus (HCV) antibodies or hepatitis B 
(HB) antigenemia, gender, age and HIV transmission group are considered as determinants 
of protease inhibitor (PI) related toxicity (1, 2). Among other potential determinants, PI 
plasma levels have been less studied although the measurement of drug concentration, i.e. 
therapeutic drug monitoring (TDM), has shown a large interest in many diseases (3-5), to 
improve efficacy and minimize toxicity. Moreover, PIs are good candidates for TDM 
because of high inter-patient variability in plasma concentrations, binding to plasma 
proteins, P450 3A4 cytochrom metabolism, short half-life, drug-food and drug-drug 
interactions (6, 7) that may lead to inadequate PIs exposure among patients receiving the 
same dose. 
Many studies in HIV-infected patients have previously focused on a relationship 
between concentration and effect, in terms of virological response (8-11), whereas toxicity 
was a secondary outcome. When adverse events have become a major problem in treated 
HIV-infected patients, data found in the literature show insufficient evidence to recommend 
a general therapeutic range, probably because only few databases have both appropriate 
pharmacokinetics and toxicity data available, like in the ANRS CO8 APROCO-
COPILOTE cohort.  
The aim of our analysis was to assess the relationship between indinavir individual 
PK characteristics, one month after initiating indinavir containing therapy, and severe 
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nephrolithiasis or any severe or serious adverse reactions (SAR), occurring in the following 
year, among patients included in an observational cohort of patients starting HAART with a 
PI-containing regimen. 
 
PATIENTS AND METHODS 
APROCO-COPILOTE cohort is a prospective observational cohort study of 1281 
HIV-1-infected patients, naive of PIs, enrolled at the initiation of a PI from May 1997 to 
June 1999, in 47 clinical centers in France, after giving written informed consent. The study 
was approved by the Paris-Cochin Ethics Committee.  
Among patients included in the APROCO-COPILOTE cohort, 513 (40.0%) have 
started their PI with indinavir 800 mg three-times-daily. Because the first plasma 
concentration was measured at month 1 (M1), we have restricted the analysis to the 282 
patients (22.0%) who have not experienced any indinavir discontinuation, nor dosage 
adjustment, nor SAR before M1 and have had a proper recording of the time interval 
between intake of last dose and plasma sampling. To ensure that no major potential 
selection bias was induced, the rate of SAR and available characteristics at M1 were 
compared between the 282 patients included and other potentially eligible patients but 
without available indinavir sampling results (n=51). 
At a random time between intake and plasma sampling, a single blood sample was 
collected at M1. Indinavir plasma concentration was measured using a validated high-
performance liquid chromatography method (12, 13). The lower limit of quantification was 
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5 ng/mL. The interday and intraday coefficients of variation of the assay were less than 
11% and 8%. 
A one-compartment model with first-order absorption and elimination was used to 
describe the PK population parameters of indinavir as shown by Brendel et al (14) and used 
by Duval et al (11). A population analysis (15) was performed to estimate both the mean 
and the inter-individual variability of the PK parameters included in this model, i.e. the 
clearance (CL) and the volume of distribution (V), the absorption rate constant (ka) being 
fixed to 0.49h
-1
. From this population analysis, the individual parameters of the 282 patients 
were derived using Bayesian estimation (16). The population analysis and the Bayesian 
estimation was performed using the FOCE method of NONMEM version 5 (UCSF, San 
Fransisco, CA). Maximum (Cmax) and trough (Cres) plasma concentrations were then 
calculated according to a classical steady-state formulae for repeated oral dose:  
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with C(t) being the plasma concentration versus time and τ the interval between two intakes 
(8 hours). 
At steady state, area under the plasma curve up to 8h after intake (AUC0-8h), was 
estimated by the Dose/CL ratio. The observed/predicted concentrations ratio (CR) was 
estimated by the ratio between the observed concentration and the predicted concentration 
at the same time using the mean population parameters estimated during the population 
analysis (10).  
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In the APROCO-COPILOTE cohort, all SAR, defined as death, event threatening 
vital prognosis, event requiring an hospitalisation or an extension of hospitalisation, 
laboratory or clinical grade 3 or 4 event 
(http://www.anrs.fr/index.php/article/articleview/1358/1/615), are prospectively collected. 
For each event, grade and causality assessment was first evaluated by the physician in 
charge of the patient and revised by a centralised Events Validation Committee, using the 
standardised definition of the National Agency for Research on AIDS and Viral Hepatitis 
(ANRS) (17). In a first analysis, only cases of nephrolithiasis among SAR related to 
indinavir occurring in the first year after initiating indinavir containing therapy, were taken 
into account because they are the most frequent and specific SAR related to indinavir use 
(18-23). Then, all SAR (including nephrolithiasis) and SAR excluding nephrolithiasis were 
studied in two secondary analyses. In all analyses, follow-up data were censored one month 
after first indinavir discontinuation or dose adjustment. 
A Cox proportional hazards regression model was used to estimate the independent 
effect of the individual indinavir PK characteristics (Cres, Cmax, AUC, CR) on the risk of 
first nephrolithiasis or SAR occurrence (depending on the analysis performed), and 
adjusted for potential other risk factors : age, gender (24, 25), body weight (26) or body 
mass index (BMI) (18) or body surface area (BSA) as estimated by the Gehan and George 
formula (27), alanine aminotransferase (ALT) and AST (28), HCV antibodies and HBs 
antigenemia serologic status (25), creatinine clearance as estimated by the Cockcroft-Gault 
formula (29), plasma HIV RNA, CD4+ T-lymphocyte count and adherence to indinavir, all 
assessed at M1. Assessment of adherence was made by a self-administrated questionnaire. 
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A patient was considered as fully adherent at the M1 visit if he/she declared that he/she had 
totally complied with his/her indinavir prescription during the 7 days before M1. 
Quantitative variables with clinically relevant thresholds were analysed as 
categorical variables, i.e. CD4+ cell count categorised as ≤200, 200 to 500 and >500/mm3, 
BMI as <19, 19 to 25 and ≥25 kg/m2. Regarding other quantitative variables, quartiles, 
median or thresholds suggested by the variable distribution, were considered. The choice of 
a potential categorisation for each variable was based on the Akaike criterion (AIC) of the 
corresponding univariate analysis, the model with the lowest AIC was chosen. In case of 
similar AIC for at least two models, the most relevant categorisation for clinical practice 
was retained. 
Variables were included in the initial multivariate Cox regression model if they 
were associated with nephrolithiasis or SAR in each univariate analysis separately with a 
p<0.25. Reduced models resulted from stepwise selection retaining only variables 
associated with nephrolithiasis or SAR at the 0.05 significance level. In the final 
multivariate model, a χ² test using the minimum p-value approach was used for all 
categorised variables associated with nephrolithiasis or SAR, in order to choose the more 
discriminating threshold among those best separating patients with nephrolithiasis or SAR 
from patients without (30). To avoid biased relative risk, it was followed by a cross 
validation (31). SAS software (version 8.2 ; SAS Institute Inc, Cary, NC, USA) was used 
for statistical analysis.  
Moreover, as the model assumed that censored follow-up was not informative, i.e. 
not related to toxicity, a robustness analysis was performed to check this hypothesis. For 
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this purpose, toxicity was defined, depending on the analysis performed, as nephrolithiasis 
only or overall SAR, indinavir discontinuations more than 30 consecutive days for any 
adverse event or for nephrolithiasis only and dose adjustments. 
 
RESULTS 
Our analysis included mainly men (78%) in their forties (Table I). The median 
indinavir concentration was 2200 ng/mL (Interquartile range (IQR): 242-6072 ng/mL) 
(Figure 1). The median sampling time interval was 3.3 h (IQR: 2.0-5.8 h) after dose intake. 
The median follow-up was 12 months. Thirty SAR occurred in the first year after initiating 
indinavir containing therapy. Twelve cases were nephrolithiasis (incidence density: 5% 
patient-years) whereas the 18 others were mainly hepatic cytolysis (n=6), 
hyperglycemia/diabetes mellitus (n=3) and death (one unexplained respiratory distress and 
one pancreatitis with lactic acidosis). The median time until the occurrence of the first 
nephrolithiasis was 5.5 months (IQR: 3.3-7.7 months). 
The rate of SAR did not differ between patients with (n=282) and without indinavir 
sampling results (n=51) (p=0.81), neither their characteristics assessed at M1.  
The mean and the inter-individual variability of the PK parameters included in the 
model, i.e. the clearance (CL) and the volume of distribution (V), according to the 
population analysis were respectively for CL : 32.1 L/h (standard error (SE): 5.7%)  and 
34% (SE: 52.4%); for V: 58.5 L (SE: 13.5%) and 227% (SE: 31%). 
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Nine of the 12 patients with nephrolithiasis were fully adherent (data missing for the 
3 others) as compared to 214 of 270 patients without nephrolithiasis. In the univariate 
analysis, only estimated Cres, Cmax, AUC and CR as well as plasma HIV RNA and age 
remained associated with a higher rate of nephrolithiasis, according to the best cut-off when 
categorised (Table II). Nephrolithiasis occurred in 9 of the 88 patients having a Cres above 
1000 ng/mL at M1 and the probability of developing a first nephrolithiasis at month 12 
(M12) was 14% when Cres was above 1000 ng/mL at M1 versus 2% when Cres was under 
1000 ng/mL (Figure 2). In the multivariate analysis (Table II), a Cres plasma concentration 
above 1000 ng/mL at M1 remained the only independent determinant of a higher rate of 
nephrolithiasis (HR = 6.7; 95% confidence interval (CI) = 1.8-25.2; p<10
-2
). The approach 
of minimum p-value associated to a cross validation confirmed the cut-off of Cres of 1000 
ng/mL and an association between a Cres above 1000 ng/mL with a higher rate of 
nephrolithiasis (HR=4.1; 95% CI=1.3-12.8; p=0.02). 
In the robustness analysis censoring indinavir discontinuations for nephrolithiasis 
and dose adjustments: a Cres above 1000 ng/mL still remained independently associated 
with a higher rate of nephrolithiasis: HR=3.9 (95% CI=1.5-10.0; p=0.005), indicating that 
the impact of informative censoring was not large enough to modify the initial conclusions. 
The median time until the occurrence of the first SAR was 4.5 months (IQR: 2.7-7.5 
months). The probability of developing a first SAR at M12 was 21.7% when Cres was above 
1000 ng/mL at M1 versus 8.2 % when Cres was under 1000 ng/mL. When any SAR were 
analysed, in a multivariate model, the following variables assessed at M1 were 
independently associated with a higher hazard of SAR: Cres above 1000 ng/mL (HR=3.3; 
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95% CI=1.1-10.1; p<0.05), plasma HIV RNA (HR=0.2 for each lower 1 log10 copies/mL; 
95% CI=0.06-0.8; p<0.05) and estimated creatinine clearance under 70 mL/min (HR=2.7; 
95% CI=1.0-7.3; p=0.05). In the robustness analysis, a Cres above 1000 ng/mL was not 
associated with a higher rate of SAR: HR=1.7 (95% CI=0.8-3.5; p=0.13).  
Unlike the two primary analyses, no significative association with Cres (p=0.37) or 
other indinavir PK characteristics was shown, when the analysis considered as outcomes 
only the 18 SAR that were not nephrolithiasis.  
 
DISCUSSION  
In this population of initially PI-naïve patients, a Cres of indinavir above 1000 
ng/mL, assessed at the steady state of HAART, was associated with a sevenfold higher rate 
of nephrolithiasis in the following year. This result potentially justifies Therapeutic Drug 
Monitoring during indinavir containing therapy. 
Whereas the APROCO-COPILOTE cohort has included 513 unselected HIV-
infected patients starting indinavir containing therapy, the present analysis was restricted to 
a sub-group of 282 patients. Although we acknowledge a potential lack of power, a 
selection bias is unlikely as the rate of SAR was similar in those patients with available 
plasma sampling and in those without. Therefore, we believe that indinavir Cres at the 
proposed threshold is strongly associated with nephrolithiasis. Non compliance with water 
intake or hot environmental temperature are known to be associated with higher incidence 
of nephrolithiasis (21, 28, 32), but were not available in our database. For instance, in a hot 
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climate, excessive sweating leading to low urinary volume, may itself predispose to 
nephrolithiasis, because of a phenomenon of dehydration. In our study, as 7 on the 12 
nephrolithiasis occurred between May and September, we believed that hot weather might 
have contributed to the occurrence of nephrolithiasis in patients having basal high indinavir 
plasma level. Even if food intake was not recorded in our database, we believe that a major 
bias due to food intake is unlikely. In the cohort, the current practice for the patients was to 
be on fasting conditions when they were sampled in the morning. If they already had their 
breakfast, we can assume that it was most often a continental breakfast, unlikely to be rich 
in fat. However, we did not record the specific information on fasting conditions in these 
patients and cannot take this into account in the analysis precisely. Finally, to our 
knowledge, indinavir pharmacokinetic characteristics are not so much affected by food 
intake, conversely to a drug such as nelfinavir. Moreover, drugs that might interact with 
indinavir (i.e. ketoconazole, rifabutine, rifampicine) have been rarely prescribed in this 
study. 
Only few previous studies have shown a relationship between higher plasma PI 
concentration and higher toxicity (20, 33-35). Two of them involved indinavir containing 
therapy but they had limitations regarding the collection of toxicity data and plasma sample 
as well as statistical analysis. Unlike Solas et al and Dieleman et al who analysed data from 
less than 70 HIV-infected patients, the present study was based on a large prospective 
cohort, thus improving statistical power. Moreover, our estimation of any relationship 
between SAR and PK characteristics such as Cres, Cmax, AUC and CR is based on 
prospective follow-up data, allowing the description of a temporal relationship which 
increases the potential for evidence based conclusions. Dieleman et al have used a case-
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control design, comparing 17 patients with nephrolithiasis to an historical control group of 
14 patients. Morevover, in their study, indinavir plasma levels were measured while 
nephrolithiasis had already occurred so that concentrations are not tested as prospective 
factors and the temporal relationship between concentrations and nephrolithiasis can not be 
properly assessed. Solas et al have shown that, in 63 patients receiving ritonavir/indinavir 
(100/800mg) twice daily, higher indinavir Cres was associated with higher rate of any 
toxicity. After initiation of ritonavir/indinavir regimen and sometimes after dose 
adjustment, indinavir Cres was assessed and compared between patients with and without 
occurrence of toxicity. Toxicity including nephrolithiasis occurred more frequently when 
Cres was above 500 ng/mL. Contrary to the present study, no specific approach was used to 
validate this cut-off. Even if the cut-off value of 1000 ng/mL, reported in our study, seems 
high compared with the range of 150 ng/mL to 500 ng/mL reported by others (6, 7, 23, 33), 
it may be explained by the modelling estimate of Cres, precisely 8 hours after last intake. 
However, it is rarely reached in clinical practice since treatment is given the preceding 
evening. Knowing the short indinavir half-life, plasma concentrations are twice lower every 
90 minutes, leading to lower observed Cres if one does take into account the time interval 
between last intake and sampling. 
Although we acknowledge that indinavir is rarely used without ritonavir in the 
actual clinical practice, we believe that the design of the present study is valuable for other 
PI-containing therapies. As already underlined, the prospective observational cohort design 
of the present study, the population PK modelling and the cut-off determination by a formal 
strategy are valuable tools that can be recommended for further toxicity-plasma levels 
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relationship studies. It also could give complementary data on potential indinavir cut-off in 
patients using ritonavir-boosted indinavir combination, since it has been well established 
that ritonavir considerably boosted indinavir Cres (38). This seems all the more important to 
early monitor indinavir concentration to avoid indinavir Cres above 1000 ng/mL as Brendel 
et al have recently shown  in patients receiving ritonavir/indinavir (100/800mg) twice daily 
that, median indinavir trough concentrations ranged from 700 ng/mL to 1250 ng/mL (14). 
No consensus exists on the therapeutic range of indinavir concentration and data 
found in the literature show insufficient evidence to recommend a general therapeutic range 
(36), surely because of a lack of available toxicity and PK data. Yet, several studies (8-10, 
37) have already shown that low PIs (or non-nucleoside reverse transcriptase inhibitor) 
plasma concentrations are associated with virologic failure. When Duval et al have shown 
that the most discriminating cut-off associated with virologic response was 194 ng/mL (11), 
in a population of fully adherent patients receiving indinavir 800 mg tid at M4 from the 
APROCO/COPILOTE cohort and using a similar PK modelling, our results demonstrate 
that Cres plasma concentration of indinavir above 1000 ng/mL is associated with a higher 
risk of nephrolithiasis occurrence. We may so suggest that the optimal therapeutic range of 
indinavir Cres could be 200 ng/mL to 1000 ng/mL. On the basis of these data, prospective 
and early assessments of indinavir Cres through therapeutic drug monitoring might be 
justified to allow dosage adjustment, while maintaining indinavir levels above efficacy 
threshold. 
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FIGURES LEGENDS 
Figure 1. Observed plasma indinavir concentrations (dots) versus time and predicted 
concentrations using mean population parameters of indinavir (solid line), ANRS CO8 
APROCO-COPILOTE sub-study (n=282), 1997-2000. 
 
Figure 2. Cumulative probability of nephrolithiasis, estimated by the Kaplan-Meier 
method, according to Cres: Cres ≥ 1000 ng/mL (bold line) versus Cres < 1000 ng/mL, ANRS 
CO8 APROCO-COPILOTE sub-study (n=282), 1997-2000. 
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Table I. Characteristics of the 282 patients included in the analysis, one month after 
initiating an indinavir containing therapy, ANRS CO8 APROCO-COPILOTE sub-study, 
1997-2000.  
Characteristic No (%) of patients or median value (IQR) 
Age (year)  37.6 (32.7-45.6) 
Male sex  219 (77.7) 
Body weight (kg)  67.0 (60.0-74.0) 
Body Mass Index (kg/m²)  22.5 (20.6-24.2) 
Body Surface Area (m
2
)  1.8  (1.7-1.9) 
HIV transmission category 
 Man who has sex with men 
 Injection drug use 
 Sex between men and women
 Haemophilia/transfusion 
 Unknown 
 
 119 (42.2) 
 45 (16.0) 
 90 (31.9) 
 10 (3.5) 
 18 (6.4) 
CDC stage C  51 (18.1) 
Plasma HIV RNA (log10 copies/mL)  2.7 (2.3-2.9) 
CD4
+
 cell count (cells/mm
3
)  377 (221-504) 
ALT (UI/L)  23.0 (16.0-36.5) 
AST (UI/L)  25.0 (19.0-33.0) 
24 
Positive HBs antigenemia  13 (5.1) 
Positive HCV antibodies  58 (21.0) 
Creatinine clearance (mL/min)  96.5 (80.0-113.7) 
indinavir pharmacokinetic characteristics 
Cmax (ng/mL) 
Cres (ng/mL) 
AUC (ng.h/mL) 
CR 
 
 6205 (4874-7 104) 
 631 (384-1 270) 
 24242 (22948-26217) 
 0.6 (0.2-1.5) 
Adherence scores 
 Low/mild 
 Full 
 
 18 (6.4) 
 223 (79.1) 
NRTIs cumulated exposition in months 
 zidovudine 
 lamivudine 
 stavudine 
 didanosine 
 zalcitabine  
 
 14.8  (17.6) 
 6.0  (7.8) 
 4.8 (5.6) 
 10.3  (12.2) 
 12.3  (10.7) 
CDC, Centres for Disease Control and Prevention; NRTI, nucleoside reverse transcriptase 
inhibitor. 
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Table II. Occurrence of nephrolithiasis in HIV-1-infected patients, in the year after initiating an indinavir containing therapy, ANRS CO8 
APROCO-COPILOTE sub-study (n=282), 1997-2000. 
   Occurrence  of  nephrolithiasis 
   Univariate analysis*  Multivariate analysis 
  
Probability of 
developing a first 
episode of 
nephrolithiasis (%)  
   Initial model Final model 
  M4 M8 M12 HR (95% CI) p  HR (95% CI) p HR (95% CI) p 
 
Estimated Cres  
 
≥ 1000 
< 1000 ng/mL 
 
2.5 
0.6 
 
8.3 
1.8 
 
14.0 
1.8 
  
7.4  (2.0-27.4) 
 1 
 
0.003   7.2 (1.0-50.1) 0.05 6.7 (1.8-25.2) 0.005 
 
Estimated Cmax  
 
< 6205 
≥ 6205 ng/mL 
 
1.5 
0.8 
 
5.8 
1.7 
 
9.0 
1.7 
  
5.2  (1.1-23.7) 
 1 
 
0.03   1.2 (0.1-13.5) 0.87 - - 
26 
 
Estimated AUC  
 
< 24242 
≥ 24242 ng.h/mL 
 
1.5 
0.8 
 
4.1 
3.4 
 
7.3 
3.4 
  
2.0  (0.6-6.7) 
 1 
 
0.25   1.6 (0.3-7.5) 0.59 - - 
 
Estimated CR 
 
< 1.3 
≥ 1.3 
 
1.1 
1.4 
 
4.7 
1.4 
 
7.0 
1.4 
  
4.7 (0.6-36.3) 
 1 
 
0.14   4.9  (0.3-76.2) 0.26 - - 
 
Plasma HIV 
RNA  
 
for each 1 log10 
copies/mL higher 
   
  
0.4  (0.1-1.8) 
 
0.20   0.4  (0.1-2.0) 0.28 - - 
 
Age 
 
< 33 years 
[33-38[ years 
≥ 38 years 
 
1.4 
1.5 
0.8 
 
1.4 
8.0 
2.6 
 
3.6 
10.0 
3.6 
  
1 
 3.1  (0.6-15.3) 
 1.1 (0.2-5.9) 
 
0.18 
 
 
  
 1 
 2.7 (0.5-14.2) 
 1.4 (0.2-8.2) 
 
0.43 
- - 
* Only variables associated with nephrolithiasis in univariate analyses with p<0.25 are listed in this table. 
M4, M8 and M12: 4, 8 and 12 months after initiating indinavir containing therapy, respectively; HR = Hazard Ratio ; CI = confidence interval 
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Figure 2 
 
Cres >= 1000 ng/mL 
Cres < 1000 ng/mL 
Cres ≥ 1000 ng/mL 
Patients (N) 
86 74 59 42 
Nephrolithiasis (n) 
0 2 6 9 
Probability (%) 
0 2.5 8.3 14.0 
 
Cres < 1000 ng/mL 
Patients (N) 
193 174 153 124 
Nephrolithiasis (n) 
0 1 3 3 
Probability (%) 
0 0.6 1.8 1.8 
